Add this topic to your myFT Digest for news straight to your inbox
Big pharma groups pay higher charges for access to most promising molecules
Industry giants forge alliances to push ahead in immunotherapies that could fetch up to $40bn a year
Net income down amid switch from pharma to speciality chemicals and lab supplies
International Edition